{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:13:08Z","timestamp":1778584388075,"version":"3.51.4"},"reference-count":0,"publisher":"Codon Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergol Immunopathol"],"abstract":"<jats:p>Asthma\u2013COPD overlap (ACO) remains therapeutically challenging, and evidence for biologic selection is limited due to the under-representation of overlap phenotypes in trials. We report a T2-high ACO patient who did not benefit from omalizumab or benralizumab but improved with dupilumab. This presents the case of a 67-year-old man with a long-term smoking history, atopy (elevated total IgE with polysensitization), eosinophilia, persistent airflow limitation, and frequent exacerbations despite optimized inhaled triple therapy. Sequential biologics included anti-IgE (omalizumab) and anti-IL-5R\u03b1 (benralizumab), with no meaningful reduction in exacerbations or improvement in lung function. After initiating dupilumab at a dose of 300 mg every 2 weeks, the patient reported a rapid improvement in symptoms, with no further exacerbations observed during the follow-up period. Pulmonary function showed a notable increase, with postbronchodilator FEV1\u00a0rising from 61 to 72% of the predicted value, and FEV1\/FVC ratio improving from 69 to 84.5%. Asthma control scores increased from 12 to 20 by Week 12. Oral corticosteroid therapy was successfully discontinued, and no adverse events requiring discontinuation of dupilumab were recorded. In T2-high ACO unresponsive to anti-IgE and anti-IL-5R\u03b1 therapies, IL-4\/IL-13 pathway inhibition with dupilumab may deliver a clinically meaningful benefit. Controlled studies are warranted to define its role in overlap phenotypes.<\/jats:p>","DOI":"10.15586\/aei.v54i3.1566","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T13:26:20Z","timestamp":1777641980000},"page":"180-183","source":"Crossref","is-referenced-by-count":0,"title":["Dupilumab after sequential omalizumab and benralizumab failure in T2-high asthma\u2013COPD overlap: A case report"],"prefix":"10.15586","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9112-8787","authenticated-orcid":false,"given":"Orbay","family":"Tutku Seren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9662-574X","authenticated-orcid":false,"given":"Aysu","family":"Okumu\u015f G\u00fc\u00e7l\u00fc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4488-1252","authenticated-orcid":false,"given":"Mehmet Emin","family":"Kocaba\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3446-9021","authenticated-orcid":false,"given":"Bet\u00fcl","family":"Aksu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2564-393X","authenticated-orcid":false,"given":"\u00dcmit","family":"\u00d6zmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4604-7173","authenticated-orcid":false,"given":"Yelda","family":"Varol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0039-302X","authenticated-orcid":false,"given":"Papatya","family":"Bayrak De\u011firmenci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6228","published-online":{"date-parts":[[2026,5,1]]},"container-title":["Allergologia et Immunopathologia"],"original-title":[],"link":[{"URL":"https:\/\/www.all-imm.com\/index.php\/aei\/article\/download\/1566\/2416","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.all-imm.com\/index.php\/aei\/article\/download\/1566\/2417","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.all-imm.com\/index.php\/aei\/article\/download\/1566\/2418","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.all-imm.com\/index.php\/aei\/article\/download\/1566\/2416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:33:13Z","timestamp":1778581993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.all-imm.com\/index.php\/aei\/article\/view\/1566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.15586\/aei.v54i3.1566","relation":{},"ISSN":["0301-0546"],"issn-type":[{"value":"0301-0546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}